Market-age growth performance following in-ovo interventions in commercial broilers: A meta-analysis
- 1Department of Animal Science and Technology, National Taiwan University, Taipei, 106, Taiwan, ROC
- 2Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, 912301, Taiwan, ROC
Abstract
In-ovo intervention has been investigated as an early-life strategy to influence post-hatch development, but its effects on growth performance at commercial market age remain inconsistent. This meta-analysis aimed to quantitatively synthesize BW, feed conversion ratio (FCR), and breast muscle yield at d 35 and d 42 in commercial broilers. A total of 1,409 records were identified in the initial database search, of which 38 studies met the eligibility criteria. Random-effects meta-analyses were conducted separately according to assessment age and comparator, while broiler strain, intervention category, and injection timing were explored as potential sources of heterogeneity. Compared with Non-injection, In-ovo intervention was associated with higher BW on d 35 (Hedges’s g = 0.686, 95% CI: 0.066 to 1.306, P = 0.03, I² = 84.55%, n = 12) and d 42 (Hedges’s g = 0.811, 95% CI: 0.086 to 1.536, P = 0.028, I² = 86.71%, n = 13), and lower FCR on d 35 (Hedges’s g = -0.358, 95% CI: -0.671 to -0.044, P = 0.025, I² = 21.67%, n = 11) and d 42 (Hedges’s g = -0.565, 95% CI: -0.852 to -0.277, P < 0.001, I² = 0%, n = 10). Compared with Control-sham, significant pooled effects were detected only for BW on d 42 (g = 0.420, P = 0.042) and FCR on d 35 (g = -0.274, P = 0.036), but not for BW on d 35 or FCR on d 42. No significant pooled effect was detected for d 42 breast muscle yield compared with Control-sham (Hedges’s g = -0.041, 95% CI: -0.27 to 0.188, P = 0.724, I² = 5.58%, n = 6) or Non-injection (g = -0.153, P = 0.291). Exploratory subgroup analyses identified significant between-subgroup differences by broiler strain and intervention category in selected BW and FCR comparisons (P = 0.006–0.030). Injection timing was significantly associated with d 42 FCR effect size relative to Control-sham (β = -0.1663, P = 0.0004), but not with other analyzed outcomes. No significant pooled differences in BW or FCR were detected between Control-sham and Non-injection. Overall, these findings provide quantitative evidence of potential market-age benefits from In-ovo interventions, while highlighting the need for standardized experimental designs and independent validation of specific intervention conditions to support reliable commercial application.
Related
- Effects of dietary nisin on growth performance, meat quality, antioxidant status, and microbial homeostasis in broilers
- Dietary esculetin improves growth performance and spleen function via the NF-κB/MAPK pathway in heat-stressed broilers.
- Effects of enzymolytic soybean meal on growth performance, intestinal morphology, cecal microbiota, and short‑chain fatty acids in broilers.
- Ethanolic extract of Polygonatum sibiricum fibrous root improves growth performance, antioxidant status, intestinal morphology, and cecal fermentation in yellow-feathered broilers
- Feeding dried cauliflower waste as a valorization method in the circular bio-economy model for broilers: effects on the performance, carcass traits and economics.
BibTeX
@article{yu2026marketage,
title = {{Market-age growth performance following in-ovo interventions in commercial broilers: A meta-analysis}},
author = {Liang-En Yu and Ti-Chun Chang and Yuan-Yu Lin},
journal = {Poultry Science},
year = {2026},
month = oct,
doi = {10.1016/j.psj.2026.107964},
url = {https://doi.org/10.1016/j.psj.2026.107964},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Market-age growth performance following in-ovo interventions in commercial broilers: A meta-analysis
AU - Liang-En Yu
AU - Ti-Chun Chang
AU - Yuan-Yu Lin
PY - 2026
DA - 2026/10/14
JO - Poultry Science
DO - 10.1016/j.psj.2026.107964
UR - https://doi.org/10.1016/j.psj.2026.107964
AB - In-ovo intervention has been investigated as an early-life strategy to influence post-hatch development, but its effects on growth performance at commercial market age remain inconsistent. This meta-analysis aimed to quantitatively synthesize BW, feed conversion ratio (FCR), and breast muscle yield at d 35 and d 42 in commercial broilers. A total of 1,409 records were identified in the initial database search, of which 38 studies met the eligibility criteria. Random-effects meta-analyses were conducted separately according to assessment age and comparator, while broiler strain, intervention category, and injection timing were explored as potential sources of heterogeneity. Compared with Non-injection, In-ovo intervention was associated with higher BW on d 35 (Hedges’s g = 0.686, 95% CI: 0.066 to 1.306, P = 0.03, I² = 84.55%, n = 12) and d 42 (Hedges’s g = 0.811, 95% CI: 0.086 to 1.536, P = 0.028, I² = 86.71%, n = 13), and lower FCR on d 35 (Hedges’s g = -0.358, 95% CI: -0.671 to -0.044, P = 0.025, I² = 21.67%, n = 11) and d 42 (Hedges’s g = -0.565, 95% CI: -0.852 to -0.277, P < 0.001, I² = 0%, n = 10). Compared with Control-sham, significant pooled effects were detected only for BW on d 42 (g = 0.420, P = 0.042) and FCR on d 35 (g = -0.274, P = 0.036), but not for BW on d 35 or FCR on d 42. No significant pooled effect was detected for d 42 breast muscle yield compared with Control-sham (Hedges’s g = -0.041, 95% CI: -0.27 to 0.188, P = 0.724, I² = 5.58%, n = 6) or Non-injection (g = -0.153, P = 0.291). Exploratory subgroup analyses identified significant between-subgroup differences by broiler strain and intervention category in selected BW and FCR comparisons (P = 0.006–0.030). Injection timing was significantly associated with d 42 FCR effect size relative to Control-sham (β = -0.1663, P = 0.0004), but not with other analyzed outcomes. No significant pooled differences in BW or FCR were detected between Control-sham and Non-injection. Overall, these findings provide quantitative evidence of potential market-age benefits from In-ovo interventions, while highlighting the need for standardized experimental designs and independent validation of specific intervention conditions to support reliable commercial application.
SN - 0032-5791
SN - 1525-3171
ER -